UK-based cancertech company Kheiron has made a significant leap in the fight against breast cancer with their AI tool, Mia, as evidenced by a recent study published in Nature Medicine. According to the new paper Mia has demonstrated the ability to increase breast cancer detection by up to 13%. This advancement could potentially reduce the rate of missed cancers by half, translating…
AI-enabled cancer diagnostics company Lunit, recently announced a financial boost with a $150M investment from its shareholders. The South Korean company, listed on the KOSDAQ, plans to invest these funds into new product development and strengthen its foothold in Western markets. The recent funding milestone is complemented by Lunit’s achievement in securing its third 510(k) clearance from the U.S. Food and Drug…
Mammogen, a precision diagnostics company, has recently completed the Clinical Laboratory Improvement Amendments (CLIA) validation for its genTRU-breast assay. This blood test is designed for the early detection of breast cancer and marks a significant step in the field of women’s health diagnostics. The foundation of Mammogen was inspired by a personal experience: the founder’s sister’s best friend, Katy, was diagnosed with…
A recent study funded by The Eve Appeal and published in The Lancet Oncology has introduced a new diagnostic test for womb cancer, known as the WID-qEC test. Developed by researchers at UCL’s Institute for Women’s Health in London (UK), the test aims to provide a quicker and less invasive alternative to the current diagnostic process. Womb cancer is the fourth most…
Andira Pharmaceuticals, a Canadian health science firm, has recently announced significant progress in the treatment of breast cancer with its pioneering formula, XOXO4. The company’s flagship oncology candidate, XOXO4, has demonstrated remarkable efficacy in regressing human breast cancer tumors. Conducted at the University of British Columbia, the study highlighted that XOXO4, a cannabinoid formula applied topically, outperformed all eight FDA-approved breast cancer-specific…
A recent landmark study announced by Eli Lilly and Company has shown significant long-term benefits of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The findings, unveiled at the 2023 European Society for Medical Oncology (ESMO) Congress, are particularly significant for those at heightened risk of cancer recurrence. The study focused on hormone receptor-positive, HER2-negative, node-positive early breast cancer. Over five…
AOA Dx, a biotech startup based in the United States, has successfully raised $17M to accelerate the development of its liquid biopsy test for ovarian cancer. This round was led by Good Growth Capital with participation from industry leading investors including RH Capital, Y Combinator, Astia, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, FemHealth Ventures, CANCER FUND along with strategic diagnostic investors, including Labcorp Venture Fund. AOA Dx’s innovative approach revolves around…
Breast Cancer Awareness Month, observed every October, is a globally recognized initiative aimed at raising awareness about breast cancer, the most prevalent cancer in women worldwide. During this month, numerous activities and campaigns are usually organized to promote early detection and screening. Pink ribbons, a symbol of breast cancer awareness, are prominently displayed, while landmarks are often illuminated in pink to draw…
